Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles from Europe
Based on 7,039 articles published since 2008
||||

These are the 7039 published articles about Psoriasis that originated from Europe during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient. 2018

Rodríguez-Jiménez, P / Mir-Viladrich, I / Chicharro, P / Solano-López, G / López-Longo, F J / Taxonera, C / Sánchez-Martínez, P / Martínez-Lacasa, X / García-Gasalla, M / Dorca, J / Arias-Guillén, M / García-García, J M / Dauden, E. ·Servicio de Dermatología, IIS-FIB, Hospital Universitario de La Princesa. Madrid, España. Electronic address: pedro.rodriguez.jimenez90@gmail.com. · Servicio de Neumología, Hospital Son Llàtzer, Palma de Mallorca, España. · Servicio de Dermatología, IIS-FIB, Hospital Universitario de La Princesa. Madrid, España. · Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España. · Servicio del Aparato Digestivo, Hospital Clínico San Carlos e Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, España. · Servicio de Enfermedades Infecciosas, Hospital del Mar, Barcelona, España. · Unidad Control de Tuberculosis, Hospital Universitari Mutua de Terrassa, Barcelona, España. · Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Son Llàtzer, Palma de Mallorca, España. · Servicio de Neumología, Hospital Universitario de Bellvitge, Hospitalet de Llobregat (Barcelona), España. · Servicio de Neumología, Hospital Universitario Central de Asturias-Instituto Nacional de Silicosis, Oviedo, España. · Servicio de Neumología, Hospital San Agustín, Avilés, España. ·Actas Dermosifiliogr · Pubmed #29871738.

ABSTRACT: Patients with chronic inflammatory diseases being treated with immunosuppressive drugs, and with tumor necrosis factor inhibitors in particular, have an increased risk of infection by Mycobacterium tuberculosis. Screening for latent tuberculosis infection and preventive therapy to reduce the risk of progression to active tuberculosis are mandatory in this group of patients. This updated multidisciplinary consensus document presents the latest expert opinions on the treatment and prevention of tuberculosis in candidates for biologic therapy and establishes recommendations based on current knowledge relating to the use of biologic agents.

2 Guideline Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis. 2018

Torre Alonso, Juan Carlos / Díaz Del Campo Fontecha, Petra / Almodóvar, Raquel / Cañete, Juan D / Montilla Morales, Carlos / Moreno, Mireia / Plasencia-Rodríguez, Chamaida / Ramírez García, Julio / Queiro, Rubén. ·Unidad de Reumatología, Hospital Monte Naranco y Universidad de Oviedo, Oviedo, España. · Unidad de Investigación, Sociedad Española de Reumatología, Madrid, España. · Unidad de Reumatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España. · Unidad de Artritis, Servicio de Reumatología, Hospital Clínic, Barcelona, España. · Servicio de Reumatología, Hospital Clínico Universitario de Salamanca, Salamanca, España. · Servicio de Reumatología, Parc Taulí Hospital Universitari, Sabadell, Barcelona, España. · Servicio de Reumatología, Hospital Universitario La Paz, IdiPaz, Madrid, España. · Unidad de Artritis, Servicio de Reumatología, IDIBAPS y Hospital Clínic, Barcelona, España. · Sección de Reumatología, Hospital Universitario Central de Asturias, Oviedo, España. Electronic address: rubenque7@yahoo.es. ·Reumatol Clin · Pubmed #29111261.

ABSTRACT: OBJECTIVE: The main purpose of this recommendation statement is to provide clinicians with the best available evidence and the best opinion agreed upon by the panelists for a rational use of synthetic disease modifying antirheumatic drugs (DMARDs) and biologicals in psoriatic arthritis (PsA) patients. The present document also focuses on important aspects in the management of PsA, such as early diagnosis, therapeutic objectives, comorbidities and optimization of treatment. METHODS: The recommendations were agreed by consensus by a panel of 8 expert rheumatologists, previously selected by the Spanish Society of Rheumatology (SER) through an open call. The phases of the work were: identification of key areas for updating the previous consensus, analysis and synthesis of scientific evidence (modified Oxford system, Centre for Evidence-based Medicine, 2009) and formulation of recommendations based on this evidence and by consensus techniques. RESULTS: Seventeen recommendations were issued for the treatment of PsA patients. Six of them were of general nature, ranging from the early diagnosis and treatment to the importance of assessing comorbidities. The other 11 were focused on the indications for DMARDs and biological therapy in the distinct clinical forms of the disease. Likewise, the situation of failure of the first biological is addressed and treatment algorithms and a table with the different biological therapies are also included. CONCLUSIONS: We present the update of SER recommendations for the treatment of PsA with DMARDs and biologics.

3 Guideline Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. 2018

Smolen, Josef S / Schöls, Monika / Braun, Jürgen / Dougados, Maxime / FitzGerald, Oliver / Gladman, Dafna D / Kavanaugh, Arthur / Landewé, Robert / Mease, Philip / Sieper, Joachim / Stamm, Tanja / Wit, Maarten de / Aletaha, Daniel / Baraliakos, Xenofon / Betteridge, Neil / Bosch, Filip van den / Coates, Laura C / Emery, Paul / Gensler, Lianne S / Gossec, Laure / Helliwell, Philip / Jongkees, Merryn / Kvien, Tore K / Inman, Robert D / McInnes, Iain B / Maccarone, Mara / Machado, Pedro M / Molto, Anna / Ogdie, Alexis / Poddubnyy, Denis / Ritchlin, Christopher / Rudwaleit, Martin / Tanew, Adrian / Thio, Bing / Veale, Douglas / Vlam, Kurt de / van der Heijde, Désirée. ·Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. · 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria. · Health Consult, Vienna, Austria. · Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany. · Department of Rheumatology, Paris Descartes University, Paris, France. · Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland. · Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada. · Division of Rheumatology, University of California, San Diego, CA, USA. · Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands. · Division of Rheumatology Research, Swedish-Providence St. Joseph Health System, University of Washington, Seattle, WA, USA. · Department of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Berlin, Germany. · Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria. · Department of Medical Humanities, VU University Medical Centre, Amsterdam, The Netherlands. · Neil Betteridge Associates, UK. · Ghent University Hospital, Ghent, Belgium. · Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. · Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK. · Department of Medicine, University of California, San Francisco, CA, USA. · Department of Rheumatology, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Paris, France. · Institute of Molecular Medicine, University of Leeds, Leeds, UK. · Seayn Medical, Voorschoten, The Netherlands. · Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. · University Health Network and University of Toronto, Toronto, Ontario, Canada. · University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, UK. · A.DI.PSO. (Associazione per la Difesa degli Psoriasici)-PE.Pso.POF (Pan European Psoriasis Patients' Organization Forum), Rome, Italy. · Centre for Rheumatology & MRC Centre for Neuromuscular Diseases, University College London, London, UK. · Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA. · German Rheumatism Research Centrer, Berlin, Germany. · Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center Rochester, New York, NY, USA. · Division of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany. · Department of Dermatology, Medical University of Vienna, Vienna, Austria. · Department of Dermatology, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands. · Department of Rheumatology, Klinikum Bielefeld, Bielefeld, Germany. · Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium. · Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. ·Ann Rheum Dis · Pubmed #28684559.

ABSTRACT: Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.

4 Guideline Recommendations for the Use of Ultrasound and Magnetic Resonance in Patients With Spondyloarthritis, Including Psoriatic Arthritis, and Patients With Juvenile Idiopathic Arthritis. 2018

Uson, Jacqueline / Loza, Estibaliz / Möller, Ingrid / Acebes, Carlos / Andreu, Jose Luis / Batlle, Enrique / Bueno, Ángel / Collado, Paz / Fernández-Gallardo, Juan Manuel / González, Carlos / Jiménez Palop, Mercedes / Lisbona, María Pilar / Macarrón, Pilar / Maymó, Joan / Narváez, Jose Antonio / Navarro-Compán, Victoria / Sanz, Jesús / Rosario, M Piedad / Vicente, Esther / Naredo, Esperanza. ·Servicio de Reumatología, Hospital Universitario de Móstoles, Móstoles, Madrid, España. · Instituto de Salud Musculoesquelética, Madrid, España. Electronic address: estibaliz.loza@inmusc.eu. · Servicio de Reumatología, Instituto Poal de Reumatología, Barcelona, España. · Servicio de Reumatología, Hospital General de Villalba, Collado Villalba, Madrid, España. · Servicio de Reumatología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España. · Servicio de Reumatología, Hospital Universitario Sant Joan d'Alacant, Sant Joan d'Alacant, Alicante, España. · Servicio de Radiología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España. · Servicio de Reumatología, Hospital Universitario Severo Ochoa, Leganés, Madrid, España. · Servicio de Radiología, Hospital Universitario Severo Ochoa, Leganés, Madrid, España. · Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España. · Servicio de Reumatología, Hospital del Mar, Barcelona, España. · Servicio de Reumatología, Hospital Universitario Clínico San Carlos, Madrid, España. · Servicio de Radiodiagnóstico, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España. · Servicio de Reumatología, Hospital Universitario La Paz, IdiPAZ, Madrid, España. · Servicio Andaluz de Salud, Sevilla, España. · Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, España. ·Reumatol Clin · Pubmed #28277255.

ABSTRACT: OBJECTIVE: To develop evidence-based recommendations on the use of ultrasound (US) and magnetic resonance imaging in patients with spondyloarthritis, including psoriatic arthritis, and juvenile idiopathic arthritis. METHODS: Recommendations were generated following a nominal group technique. A panel of experts (15 rheumatologists and 3 radiologists) was established in the first panel meeting to define the scope and purpose of the consensus document, as well as chapters, potential recommendations and systematic literature reviews (we used and updated those from previous EULAR documents). A first draft of recommendations and text was generated. Then, an electronic Delphi process (2 rounds) was carried out. Recommendations were voted from 1 (total disagreement) to 10 (total agreement). We defined agreement if at least 70% of participants voted≥7. The level of evidence and grade or recommendation was assessed using the Oxford Centre for Evidence Based Medicine levels of evidence. The full text was circulated and reviewed by the panel. The consensus was coordinated by an expert methodologist. RESULTS: A total of 12 recommendations were proposed for each disease. They include, along with explanations of the validity of US and magnetic resonance imaging regarding inflammation and damage detection, diagnosis, prediction (structural damage progression, flare, treatment response, etc.), monitoring and the use of US guided injections/biopsies. CONCLUSIONS: These recommendations will help clinicians use US and magnetic resonance imaging in patients with spondyloarthritis and juvenile idiopathic arthritis.

5 Guideline Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. 2017

Chiricozzi, Andrea / Pimpinelli, Nicola / Ricceri, Federica / Bagnoni, Giovanni / Bartoli, Laura / Bellini, Mauro / Brandini, Luca / Caproni, Marzia / Castelli, Antonio / Fimiani, Michele / Marsili, Franco / Mazzatenta, Carlo / Niccoli, Maria Chiara / Panduri, Salvatore / Pellegrino, Michele / Sirna, Riccardo / Volpi, Walter / Romanelli, Marco / Prignano, Francesca. ·Dermatology Department, University of Pisa. Via Roma 67, 56126 Pisa, Italy. · Department of Surgery and Translational Medicine, Section of Dermatology and Venereology, University of Florence School of Medicine, Florence, Italy. · Dermatology Unit, Livorno Hospital, ASL 6, Livorno, Italy. · Dermatology Unit, San Jacopo Hospital, ASL 3, Pistoia, Italy. · Dermatology Unit, Carrara Hospital, USL nordovest, Carrara, Italy. · Dermatology Unit, San Giuseppe Hospital, ASL 11, Empoli, Italy. · Dermatologic Rare Diseases and Skin Immunopathology Unit, University of Florence, Florence, Italy. · U.O. Dermatology I, University of Florence, Florence, Italy. · Dermatology Unit, San Donato Hospital, ASL 8, Arezzo, Italy. · Departmernt of Dermatology, Division of Medical, Surgical and Neurosciences, University of Siena, Siena Italy. · Dermatology Unit, Versilia Hospital, ASL 12, Lido di Camaiore, Lucca, Italy. · Dermatology Unit, Campo di Marte Hospital, ASL 2, Lucca, Italy. · Dermatology Unit, Prato Hospital, ASL 4, Prato, Italy. · Dermatology Unit, Misericordia Hospital, ASL 9, Grosseto, Italy. ·Dermatol Ther · Pubmed #28940579.

ABSTRACT: Psoriasis is a chronic and relapsing inflammatory skin disease, clinically characterized by erythematous and scaly plaques. Treatment approach is mainly driven by disease severity, though several factors should be considered in order to identify the optimal therapeutic choice. Mild psoriasis may be treated with a wide array of topical agents including corticosteroids, vitamin D analogs, keratolytics, and calcipotriol/betamethasone propionate compound. Because guidelines may not provide practical indications regarding the therapeutic approach, the use of topical agents in psoriasis is more individually tailored. In order to homogenize the standard of care, at least in a local setting, we collected the real-life-based recommendations for the use of topical therapies from an expert panel, the Tuscany Consensus Group on Psoriasis, representing all leading centers for psoriasis established in Tuscany. With this document, this consensus group sought to define principles guiding the selection of therapeutic agents with straightforward recommendations derived from a real-life setting.

6 Guideline European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. 2017

Nast, A / Spuls, P I / van der Kraaij, G / Gisondi, P / Paul, C / Ormerod, A D / Saiag, P / Smith, C H / Dauden, E / de Jong, E M / Feist, E / Jobling, R / Maccarone, M / Mrowietz, U / Papp, K A / Reich, K / Rosumeck, S / Talme, T / Thio, H B / van de Kerkhof, P / Werner, R N / Dressler, C. ·Division of Evidence-Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. · Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands. · Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy. · Department of Dermatology, Paul Sabatier University, Toulouse, France. · Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen, UK. · Service de Dermatologie, Hôpital Ambroise Paré Université Paris V, Boulogne, France. · St Johns Institute of Dermatology, Guys and St Thomas' Hospital Foundation Trust, London, UK. · Hospital Universitario de la Princesa, Madrid, Spain. · Radboud University medical center and Radboud University, Nijmegen, The Netherlands. · Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany. · Cambridge, UK. · Roma, Italy. · Department of Dermatology, Psoriasis-Center University Medical Center Schleswig Holstein, Kiel, Germany. · Waterloo, Canada. · Dermatologikum Hamburg, Hamburg, Germany. · Section of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden. ·J Eur Acad Dermatol Venereol · Pubmed #28895202.

ABSTRACT: -- No abstract --

7 Guideline Treatment of severe psoriasis in children: recommendations of an Italian expert group. 2017

Fortina, Anna Belloni / Bardazzi, Federico / Berti, Samantha / Carnevale, Claudia / Di Lernia, Vito / El Hachem, Maya / Neri, Iria / Gelmetti, Carlo Mario / Lora, Viviana / Mazzatenta, Carlo / Milioto, Mirella / Moretta, Gaia / Patrizi, Annalisa / Peris, Ketty / Villani, Alberto. ·Pediatric Dermatology Unit, Department of Medicine, University of Padua, Via Gallucci, 4, 35128, Padova, Italy. anna.bellonifortina@gmail.com. · Dermatology Unit, Department of Specialistic, Diagnostic and Experimental Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. · Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy. · Dermatology Unit, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy. · Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy. · Pediatric Dermatology Unit, Fondazione IRCCS Ca' Granda "Ospedale Maggiore Policlinico", Milan Department of Pathophysiology and Transplantation, University of Milan, Milano, Italy. · Center for the Study and Treatment of Psoriasis, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy. · Dermatology Unit, "Campo di Marte" Hospital, Azienda USL 2, Lucca, Italy. · Dermatology Unit, Ospedale Civico di Cristina Benfratelli, Palermo, Italy. · Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy. · General Pediatrics and Infectious Disease, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy. ·Eur J Pediatr · Pubmed #28836064.

ABSTRACT: This article provides comprehensive recommendations for the systemic treatment of severe pediatric psoriasis based on evidence obtained from a systematic review of the literature and the consensus opinion of expert dermatologists and pediatricians. For each systemic treatment, the grade of recommendation (A, B, C) based on the treatment's approval by the European Medicines Agency for childhood psoriasis and the experts' opinions is discussed. The grade of recommendation for narrow-band-ultraviolet B phototherapy, cyclosporine, and retinoids is C, while that for methotrexate is C/B. The use of adalimumab, etanercept, and ustekinumab has a grade A recommendation. No conventional systemic treatments are approved for pediatric psoriasis. Adalimumab is approved by the European Medicines Agency as a first-line treatment for severe chronic plaque psoriasis in children (≥ 4 years old) and adolescents. Etanercept and ustekinumab are approved as second-line therapy in children ≥ 6 and ≥ 12 years, respectively. CONCLUSION: A treatment algorithm as well as practical tools (i.e., tabular summaries of differential diagnoses, treatment mechanism of actions, dosing regimens, control parameters) are provided to assist in therapeutic reasoning and decision-making for individual patients. These treatment recommendations are endorsed by major Italian Pediatric and Dermatology Societies. What is Known: • Guidelines for the treatment of severe pediatric psoriasis are lacking and most traditional systemic treatments are not approved for use in young patients. Although there has been decades of experience with some of the traditional agents such as phototherapy, acitretin, and cyclosporine in children, there are no RCTs on their pediatric use while RCTs investigating new biologic agents have been performed. What is New: • In this manuscript, an Italian multidisciplinary team of experts focused on treatment recommendations for severe forms of psoriasis in children based on an up-to-date review of the literature and experts' opinions.

8 Guideline British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. 2017

Smith, C H / Jabbar-Lopez, Z K / Yiu, Z Z / Bale, T / Burden, A D / Coates, L C / Cruickshank, M / Hadoke, T / MacMahon, E / Murphy, R / Nelson-Piercy, C / Owen, C M / Parslew, R / Peleva, E / Pottinger, E / Samarasekera, E J / Stoddart, J / Strudwicke, C / Venning, V A / Warren, R B / Exton, L S / Mohd Mustapa, M F. ·St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, U.K. · The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9NT, U.K. · British Dermatology Nursing Group representative, Aneurin Bevan Health Board, Wales, U.K. · Department of Dermatology, Royal Infirmary of Edinburgh, Edinburgh, EH3 9HA, U.K. · British Society for Rheumatology, Chapel Allerton Hospital, Leeds, LS7 4SA, U.K. · Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, U.K. · National Guideline Centre, Royal College of Physicians, London, NW1 4LE, U.K. · Patient representatives. · Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, U.K. · Department of Dermatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, U.K. · Women's Health Academic Centre, Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, U.K. · Department of Dermatology, East Lancashire Hospitals NHS Trust, Burnley, BB10 2PQ, U.K. · Department of Dermatology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, L7 8XP, U.K. · Independent chair, Healthcare Quality Improvement Partnership, London, EC2Y 9AE, U.K. · Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, U.K. · British Association of Dermatologists, London, W1T 5HQ, U.K. ·Br J Dermatol · Pubmed #28513835.

ABSTRACT: -- No abstract --

9 Guideline Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. 2017

Raaby, Line / Zachariae, Claus / Østensen, Monika / Heickendorff, Lene / Thielsen, Peter / Grønbæk, Henning / Skov, Lone / Kyvsgaard, Nini / Madsen, Jakob T / Heidenheim, Michael / Funding, Anne T / Strauss, Gitte / Lindberg, Rune / Iversen, Lars. ·Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. ·Acta Derm Venereol · Pubmed #27958611.

ABSTRACT: Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.

10 Guideline EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. 2017

Agca, R / Heslinga, S C / Rollefstad, S / Heslinga, M / McInnes, I B / Peters, M J L / Kvien, T K / Dougados, M / Radner, H / Atzeni, F / Primdahl, J / Södergren, A / Wallberg Jonsson, S / van Rompay, J / Zabalan, C / Pedersen, T R / Jacobsson, L / de Vlam, K / Gonzalez-Gay, M A / Semb, A G / Kitas, G D / Smulders, Y M / Szekanecz, Z / Sattar, N / Symmons, D P M / Nurmohamed, M T. ·Departments of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade & VU University Medical Center, Amsterdam, The Netherlands. · Department of Rheumatology, Preventive Cardio-Rheuma Clinic, Diakonhjemmet Hospital, Oslo, Norway. · College of Medical, Veterinary and Life Sciences, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. · Internal and Vascular Medicine, VU University Medical Center, Amsterdam, The Netherlands. · Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. · Department of Rheumatology, Paris Descartes University, Hôpital Cochin. Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris, France. · Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria. · IRCCS Galeazzi Orthopedic Institute, Milan, Italy. · Institute for Regional Health Research, University of Southern Denmark, Odense, Denmark. · Sygehus Sønderjylland (Hospital of Southern Jutland), Aabenraa, Denmark. · King Christian 10's Hospital for Rheumatic Diseases, Graasten, Denmark. · Department of Public Health and Clinical Medicine/Rheumatology, University of Umeå, Umeå, Sweden. · PARE (patient research partners), Sint-Joris-Weert, Belgium. · Romanian League Against Rheumatism (Vice-President) and Board Member (General Secretary) of AGORA, the Platform of S-E organisations for patients with RMDs, Bucharest, Romania. · Oslo University Hospital, Ullevål, Center for Preventive Medicine and Medical Faculty, University of Oslo, Oslo, Norway. · Department of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg and Section of Rheumatology, Lund, Sweden. · Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. · Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. · University of Cantabria, IDIVAL, Santander, Spain. · Head of Research and Development, Academic Affairs Dudley Group NHS Foundation Trust, Arthritis Research UK Centre for Epidemiology, University of Manchester, Russells Hall Hospital, Clinical Research Unit, Dudley, UK. · Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, University of Debrecen, Debrecen, Hungary. · Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK. · Department of Rheumatology and Musculoskeletal Epidemiology, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, UK. · Department of Rheumatology Reade, Amsterdam Rheumatology and Immunology Center, Reade & VU University Medical Center, Amsterdam, The Netherlands. ·Ann Rheum Dis · Pubmed #27697765.

ABSTRACT: Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.

11 Guideline Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. 2016

Kolios, Antonios G A / Yawalkar, Nikhil / Anliker, Mark / Boehncke, Wolf-Henning / Borradori, Luca / Conrad, Curdin / Gilliet, Michel / Häusermann, Peter / Itin, Peter / Laffitte, Emmanuel / Mainetti, Carlo / French, Lars E / Navarini, Alexander A. ·Department of Dermatology, Zurich University Hospital, Zurich, Switzerland. ·Dermatology · Pubmed #27322375.

ABSTRACT: Psoriasis vulgaris is a common, chronic inflammatory skin disease with a prevalence of 1.5-2% in Western industrialized countries. A relevant percentage of patients suffer from moderate-to-severe psoriasis and experience a significant reduction in quality of life. The choice of an adequate therapy could help to prevent disease and exacerbation of comorbidity, which could increase quality of life, avoid hospitalization and avoid reduction of working days. The present guidelines are focused on the initiation and management of systemic therapies in cases of moderate-to-severe plaque-type psoriasis in adults to optimize treatment response, adherence and quality of life. This first version of the Swiss S1 guidelines presents therapeutic recommendations which are based on a systematic literature search as well as an informal expert consensus of dermatologists in Switzerland.

12 Guideline Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. 2016

Coates, Laura C / Kavanaugh, Arthur / Mease, Philip J / Soriano, Enrique R / Laura Acosta-Felquer, Maria / Armstrong, April W / Bautista-Molano, Wilson / Boehncke, Wolf-Henning / Campbell, Willemina / Cauli, Alberto / Espinoza, Luis R / FitzGerald, Oliver / Gladman, Dafna D / Gottlieb, Alice / Helliwell, Philip S / Husni, M Elaine / Love, Thorvardur J / Lubrano, Ennio / McHugh, Neil / Nash, Peter / Ogdie, Alexis / Orbai, Ana-Maria / Parkinson, Andrew / O'Sullivan, Denis / Rosen, Cheryl F / Schwartzman, Sergio / Siegel, Evan L / Toloza, Sergio / Tuong, William / Ritchlin, Christopher T. ·Leeds Institute of Rheumatic and Musculoskeletal Medicine and University of Leeds, Leeds, UK. · University of California at San Diego. · Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington. · Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. · University of Southern California, Keck School of Medicine, Los Angeles. · Hospital Militar Central and Universidad Militar Nueva Grenada, Bogotá, Colombia. · Geneva University Hospital, Geneva, Switzerland. · Toronto Western Hospital, Toronto, Ontario, Canada. · University of Cagliari, Monserrato Campus, Cagliari, Italy. · Louisiana State University Health Sciences Center, New Orleans. · St. Vincent's University Hospital, The Conway Institute for Biomolecular Research, and University College Dublin, Dublin, Ireland. · University of Toronto and Toronto Western Research Institute, Toronto, Ontario, Canada. · Tufts Medical Center, Boston, Massachusetts. · Leeds Institute of Rheumatic and Musculoskeletal Medicine and University of Leeds, Leeds, UK, and Bradford Hospitals NHS Foundation Trust, Bradford, UK. · Cleveland Clinic Foundation, Cleveland, Ohio. · University of Iceland and Landspitali University Hospital, Reykjavik, Iceland. · University of Molise, Campobasso, Italy. · Royal National Hospital for Rheumatic Diseases, Bath, UK. · University of Queensland, Brisbane, Queensland, Australia. · University of Pennsylvania, Philadelphia. · Johns Hopkins University School of Medicine, Baltimore, Maryland. · Chapel Allerton Hospital, Leeds, UK. · St. Vincent's University Hospital, Dublin, Ireland. · Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada. · Hospital for Special Surgery, New York, New York. · Arthritis and Rheumatism Associates, Rockville, Maryland. · Ministry of Health, San Fernando del Valle de Catamarca, Argentina. · University of California, Davis. · University of Rochester Medical Center, Rochester, New York. ·Arthritis Rheumatol · Pubmed #26749174.

ABSTRACT: OBJECTIVE: To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA). METHODS: GRAPPA rheumatologists, dermatologists, and PsA patients drafted overarching principles for the management of PsA, based on consensus achieved at face-to-face meetings and via online surveys. We conducted literature reviews regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, dactylitis, skin disease, and nail disease) and convened a new group to identify pertinent comorbidities and their effect on treatment. Finally, we drafted treatment recommendations for each of the clinical manifestations and assessed the level of agreement for the overarching principles and treatment recommendations among GRAPPA members, using an online questionnaire. RESULTS: Six overarching principles had ≥80% agreement among both health care professionals (n = 135) and patient research partners (n = 10). We developed treatment recommendations and a schema incorporating these principles for arthritis, spondylitis, enthesitis, dactylitis, skin disease, nail disease, and comorbidities in the setting of PsA, using the Grading of Recommendations, Assessment, Development and Evaluation process. Agreement of >80% was reached for approval of the individual recommendations and the overall schema. CONCLUSION: We present overarching principles and updated treatment recommendations for the key manifestations of PsA, including related comorbidities, based on a literature review and consensus of GRAPPA members (rheumatologists, dermatologists, other health care providers, and patient research partners). Further updates are anticipated as the therapeutic landscape in PsA evolves.

13 Guideline European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. 2016

Gossec, L / Smolen, J S / Ramiro, S / de Wit, M / Cutolo, M / Dougados, M / Emery, P / Landewé, R / Oliver, S / Aletaha, D / Betteridge, N / Braun, J / Burmester, G / Cañete, J D / Damjanov, N / FitzGerald, O / Haglund, E / Helliwell, P / Kvien, T K / Lories, R / Luger, T / Maccarone, M / Marzo-Ortega, H / McGonagle, D / McInnes, I B / Olivieri, I / Pavelka, K / Schett, G / Sieper, J / van den Bosch, F / Veale, D J / Wollenhaupt, J / Zink, A / van der Heijde, D. ·Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Paris, France Department of rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France. · Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria Second Department of Medicine, Hietzing Hospital, Vienna, Austria. · Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands. · EULAR, representing People with Arthritis/Rheumatism in Europe (PARE), London, UK. · Research Laboratory and Clinical Division of Rheumatology, Department of Internal Medicine, University of Genova, Viale Benedetto, Italy. · Medicine Faculty, Paris Descartes University, Paris, France Rheumatology B Department, APHP, Cochin Hospital, Paris, France. · Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, UK Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. · Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands Atrium Medical Center, Heerlen, The Netherlands. · North Devon, UK. · Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. · Rheumazentrum Ruhrgebiet, Herne and Ruhr-Universität Bochum, Herne, Germany. · Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Germany. · Arthritis Unit, Department of Rheumatology, Hospital Clínic and IDIBAPS, Barcelona, Spain. · Belgrade University School of Medicine, Belgrade, Serbia. · Department of Rheumatology, St. Vincent's University Hospital and Conway Institute, University College Dublin, Dublin, Ireland. · Section of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden Sweden and School of Business, Engineering and Science, Halmstad University, Halmstad, Sweden. · Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK. · Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. · Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven, Belgium Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium. · Department of Dermatology, University Hospital Münster, Münster, Germany. · A.DI.PSO. (Associazione per la Difesa degli Psoriasici)-PE.Pso.POF (Pan European Psoriasis Patients' Organization Forum), Rome, Italy. · Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. · Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy. · Institute and Clinic of Rheumatology Charles University Prague, Czech Republic. · Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany. · Department of Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany. · Ghent University Hospital, Ghent, Belgium. · Centre for Arthritis and Rheumatic Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland. · Schoen Klinik Hamburg, Rheumatology and Clinical Immunology, Hamburg, Germany. · Department of Rheumatology and Clinical Immunology, German Rheumatism Research Centre Berlin, Charité-University Medicine Berlin, Germany. ·Ann Rheum Dis · Pubmed #26644232.

ABSTRACT: BACKGROUND: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. METHODS: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. RESULTS: The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. CONCLUSIONS: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.

14 Guideline European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. 2015

Nast, A / Gisondi, P / Ormerod, A D / Saiag, P / Smith, C / Spuls, P I / Arenberger, P / Bachelez, H / Barker, J / Dauden, E / de Jong, E M / Feist, E / Jacobs, A / Jobling, R / Kemény, L / Maccarone, M / Mrowietz, U / Papp, K A / Paul, C / Reich, K / Rosumeck, S / Talme, T / Thio, H B / van de Kerkhof, P / Werner, R N / Yawalkar, N. ·Division of Evidence Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany. · Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy. · Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen, UK. · Service de Dermatologie, Hôpital Ambroise Paré Université Paris V, Boulogne, France. · Clinical Lead for Dermatology, St Johns Institute of Dermatology, St Thomas' Hospital, London, UK. · Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands. · Third Faculty of Medicine, Department of Dermatology, Charles University, Prague, Czech Republic. · Department of Dermatology, Hôpital Saint-Louis, Paris, France. · St. Johns Institute of Dermatology, St. Thomas' Hospital, London, UK. · Hospital Universitario de la Princesa, Madrid, Spain. · University Medical Center Nijmegen St Radboud, Nijmegen, The Netherlands. · Medizinische Klinik mit Schwerpunkt Rheumatologie u. klinische Immonologie, Charité - Universitätsmedizin Berlin, Berlin, Germany. · Cambridge, UK. · SZTE Borgyogyaszati Klinika, Szeged, Hungary. · Roma, Italy. · Department of Dermatology, Psoriasis-Center University Medical Center Schleswig Holstein, Kiel, Germany. · Waterloo, Canada. · Department of Dermatology, Paul Sabatier University, Toulouse, France. · Dermatologikum Hamburg, Hamburg, Germany. · Section of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden. · Department of Dermatology, Erasmus University, Rotterdam, The Netherlands. · Department of Dermatology, University Hospital Nijmegen, Nijmegen, The Netherlands. · Department of Dermatology, Inselspital, Universitätsklinik für Dermatologie, Bern, Switzerland. ·J Eur Acad Dermatol Venereol · Pubmed #26481193.

ABSTRACT: -- No abstract --

15 Guideline Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--EDF in cooperation with EADV and IPC. 2015

Nast, A / Jacobs, A / Rosumeck, S / Werner, R N. ·Division of Evidence Based Medicine, Klinik für Dermatologie, Allergologie und Venerologie, Charité - Universitätsmedizin Berlin, Berlin, Germany. ·J Eur Acad Dermatol Venereol · Pubmed #26471228.

ABSTRACT: -- No abstract --

16 Guideline Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference. 2014

Altomare, G / Ayala, F / Bardazzi, F / Bellia, G / Chimenti, S / Colombo, D / Flori, M L / Girolomoni, G / Micali, G / Parodi, A / Peris, K / Vena, G A / Anonymous1420806. ·IRCCS Galeazzi, University of Milan, Milan, Italy - giampiero.girolomoni@univr.it. ·G Ital Dermatol Venereol · Pubmed #25213388.

ABSTRACT: Cyclosporine A (CsA) efficacy and safety have been proven in various dermatoses both in adults and in children even as long-term treatment. Over the last 25 years, Italian dermatologists have gathered relevant experience about CsA treatment for psoriasis and atopic dermatitis. This paper has been developed by an Italian Consensus Conference and it is aimed at providing recommendations based on real-world clinical experience in adult patients, consistent with efficacy and safety data arising from the scientific literature. The paper is mainly focused on the analysis of the optimal therapeutic schemes for psoriasis and atopic dermatitis, in terms of doses and treatment duration, according to individual characteristics and to the severity of the disease. Moreover, it overviews ideal management, taking into account pharmacological interactions, influence of comorbidities, and the most common adverse events related to CsA treatment.

17 Guideline Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles). 2014

Sánchez-Regaña, M / Aldunce Soto, M J / Belinchón Romero, I / Ribera Pibernat, M / Lafuente-Urrez, R F / Carrascosa Carrillo, J M / Ferrándiz Foraster, C / Puig Sanz, L / Daudén Tello, E / Vidal Sarró, D / Ruiz-Villaverde, R / Fonseca Capdevila, E / Rodríguez Cerdeira, M C / Alsina Gibert, M M / Herrera Acosta, E / Marrón Moya, S E / Anonymous550795. ·Servicio de Dermatología, Hospital Universitari Sagrat Cor, Barcelona, España. Electronic address: msanchezreg@hotmail.com. · Servicio de Dermatología, Hospital Universitari Sagrat Cor, Barcelona, España. · Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, España. · Servicio de Dermatología, Hospital Universitari de Sabadell-Corporació Parc Taulí, Sabadell, Universitat Autònoma de Barcelona, Barcelona, España. · Servicio de Dermatología, Hospital Reina Sofía, Tudela, España. · Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol. Badalona, Universitat Autònoma de Barcelona, Barcelona, España. · Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España. · Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid, España. · Servicio de Dermatología, Hospital de Sant Joan Despí-Moisès Broggi, Sant Joan Despí, Barcelona, España. · Servicio de Dermatología, Complejo Hospitalario de Jaén, Jaén, España. · Servicio de Dermatología, Complejo Hospitalario Universitario de La Coruña, La Coruña, España. · Servicio de Dermatología, Complejo Hospitalario Universitario de Vigo, Vigo, España. · Servicio de Dermatología, Hospital Clínic, Universitat de Barcelona, Barcelona, España. · Servicio de Dermatología, Hospital Universitario Virgen de la Victoria, Málaga, España. · Unidad Clínica de Dermatología, Hospital de Alcañiz, Instituto Aragonés de Ciencias de la Salud, Alcañiz, España. ·Actas Dermosifiliogr · Pubmed #24852726.

ABSTRACT: Psoriatic lesions affecting the scalp, nails, palms, and the soles of the feet are described as difficult-to-treat psoriasis and require specific management. Involvement of these sites often has a significant physical and emotional impact on the patient and the lesions are difficult to control with topical treatments owing to inadequate penetration of active ingredients and the poor cosmetic characteristics of the vehicles used. Consequently, when difficult-to-treat sites are involved, psoriasis can be considered severe even though the lesions are not extensive. Scant information is available about the use of biologic therapy in this setting, and published data generally comes from clinical trials of patients who also had moderate to severe extensive lesions or from small case series and isolated case reports. In this article we review the quality of the scientific evidence for the 4 biologic agents currently available in Spain (infliximab, etanercept, adalimumab, and ustekinumab) and report level i evidence for the use of biologics to treat nail psoriasis (level of recommendation A) and a somewhat lower level of evidence in the case of scalp involvement and palmoplantar psoriasis.

18 Guideline Recommendations for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists: a Delphi study. 2014

Cañete, J D / Daudén, E / Queiro, R / Aguilar, M D / Sánchez-Carazo, J L / Carrascosa, J M / Carretero, G / García-Vivar, M L / Lázaro, P / López-Estebaranz, J L / Montilla, C / Ramírez, J / Rodríguez-Moreno, J / Puig, L. ·Servicio de Reumatología, Hospital Clínic de Barcelona e IDIBAPS, Barcelona, Spain. · Servicio de Dermatología, IIS-Princesa, Hospital Universitario La Princesa, Madrid, Spain. · Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Spain. · Técnicas Avanzadas de Investigación en Servicios de Salud (TAISS), Madrid, Spain. · Servicio de Dermatología, Hospital General de Valencia, Valencia, Spain. · Servicio de Dermatología, Hospital Universitari Germans Trias y Pujol, Badalona, Barcelona, Spain. · Servicio de Dermatología, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain. · Servicio de Reumatología, Hospital Universitario Basurto, Bilbao, Spain. · Servicio de Dermatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain. · Servicio de Reumatología, Hospital Universitario de Salamanca, Salamanca, Spain. · Servicio de Reumatología, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. · Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Electronic address: lpuig@santpau.cat. ·Actas Dermosifiliogr · Pubmed #24657018.

ABSTRACT: Psoriatic arthritis, a chronic inflammatory musculoskeletal disease that is associated with psoriasis, causes joint erosions, accompanied by loss of function and quality-of-life. The clinical presentation is variable, with extreme phenotypes that can mimic rheumatoid arthritis or ankylosing spondylitis. Because psoriasis usually presents before psoriatic arthritis, the dermatologist plays a key role in early detection of the latter. As many treatments used in psoriasis are also used in psoriatic arthritis, treatment recommendations should take into consideration the type and severity of both conditions. This consensus paper presents guidelines for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists. The paper was drafted by a multidisciplinary group (6rheumatologists, 6dermatologists, and 2epidemiologists) using the Delphi method and contains recommendations, tables, and algorithms for the diagnosis, referral, and treatment of patients with psoriatic arthritis.

19 Guideline Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dutch Society of Dermatology and Venereology. 2014

Zweegers, J / de Jong, E M G J / Nijsten, T E C / de Bes, J / te Booij, M / Borgonjen, R J / van Cranenburgh, O D / van Deutekom, H / van Everdingen, J J E / de Groot, M / Van Hees, C L M / Hulshuizen, H / Koek, M B G / de Korte, W J A / de Korte, J / Lecluse, L L A / Pasch, M C / Poblete-Gutiérrez, P A / Prens, E P / Seyger, M M B / Thio, H B / Torcque, L A / de Vries, A C Q / van de Kerkhof, P C M / Spuls, Ph I. ·Dutch Society of Dermatology and Venereology. j.zweegers@derma.umcn.nl. ·Dermatol Online J · Pubmed #24656281.

ABSTRACT: This document provides a summary of the Dutch S3-guidelines on the treatment of psoriasis. These guidelines were finalized in December 2011 and contain unique chapters on the treatment of psoriasis of the face and flexures, childhood psoriasis as well as the patient's perspective on treatment. They also cover the topical treatment of psoriasis, photo(chemo)therapy, conventional systemic therapy and biological therapy.

20 Guideline Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. 2014

Wendling, Daniel / Lukas, Cédric / Paccou, Julien / Claudepierre, Pascal / Carton, Laurence / Combe, Bernard / Goupille, Philippe / Guillemin, Francis / Hudry, Christophe / Miceli-Richard, Corinne / Dougados, Maxime / Anonymous2320781. ·Service de rhumatologie, université de Franche-Comté (EA 4266), CHRU de Besançon, boulevard Fleming, 25030 Besançon, France. Electronic address: dwendling@chu-besancon.fr. · Hôpital Lapeyronie, Montpellier, Institut Universitaire de Recherche Clinique (EA2415), 34000 Montpellier, France. · Département de rhumatologie, CHU d'Amiens, 80000 Amiens, France; Inserm U1088, UFR Médecine/Pharmacie, Université de Picardie Jules-Verne, 80000 Amiens, France. · Université Paris Est Créteil, Laboratoire d'Investigation Clinique (LIC) EA4393, 94010 Créteil, France; AP-HP, Hôpital Henri-Mondor, Service de Rhumatologie, 94000 Créteil, France. · Association France Spondylarthrites, 19000 Tulle, France. · Departement de Rhumatologie, CHU Lapeyronie,Université Montpellier 1, 34000 Montpellier, France. · CHRU de Tours, service de rhumatologie, UMR CNRS 7292, Université François-Rabelais de Tours, 37000 Tours, France. · Inserm CIC-EC, CHU de Nancy, Service épidémiologie et évaluation cliniques, 54505 Nancy, France. · Cabinet de Rhumatologie, 75008 Paris, France. · Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, 94270 Le Kremlin-Bicêtre, France. · Paris-Descartes University, Medicine Faculty, AP-HP, Cochin hospital, Rheumatology B Department, 75014 Paris, France. ·Joint Bone Spine · Pubmed #24412120.

ABSTRACT: OBJECTIVE: To develop practice guidelines for the everyday management of patients with spondyloarthritis (including psoriatic arthritis), by updating previous national and international recommendations, based on a review of recently published data. METHODS: A task force and a multidisciplinary literature review group were established. The task force identified the issues that remained unresolved. Based on existing recommendations and recent publications, the task force developed practice guidelines, which were revised by the literature review group and graded according to AGREE. RESULTS: Practice guidelines for the management of spondyloarthritis are reported. After a review of the general diagnostic principles, 30 practice guidelines are given: 5 on general principles, 4 on the management strategy, 5 on non-pharmacological treatments, 7 on conventional pharmacological treatments, 6 on biotherapies, and 3 on surgical treatments and follow-up. CONCLUSION: The updated practice guidelines reported here constitute a global framework that can guide physicians in the everyday management of spondyloarthritis.

21 Guideline Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. 2013

Puig, L / Carrascosa, J M / Carretero, G / de la Cueva, P / Lafuente-Urrez, R F / Belinchón, I / Sánchez-Regaña, M / García-Bustínduy, M / Ribera, M / Alsina, M / Ferrándiz, C / Fonseca, E / García-Patos, V / Herrera, E / López-Estebaranz, J L / Marrón, S E / Moreno, J C / Notario, J / Rivera, R / Rodriguez-Cerdeira, C / Romero, A / Ruiz-Villaverde, R / Taberner, R / Vidal, D / Anonymous1050769. ·Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: lpuig@santpau.cat. ·Actas Dermosifiliogr · Pubmed #24018211.

ABSTRACT: Biologic therapy is a well-established strategy for managing moderate and severe psoriasis. Nevertheless, the high cost of such therapy, the relatively short span of clinical experience with biologics, and the abundance of literature now available on these agents have made evidence-based and consensus-based clinical guidelines necessary. The ideal goal of psoriasis treatment is to achieve complete or nearly complete clearing of lesions and to maintain it over time. Failing that ideal, the goal would be to reduce involvement to localized lesions that can be controlled with topical therapy. Although current evidence allows us to directly or indirectly compare the efficacy or risk of primary or secondary failure of available biologics based on objective outcomes, clinical trial findings cannot be directly translated to routine practice. As a result, the prescribing physician must tailor the treatment regimen to the individual patient. This update of the clinical practice guidelines issued by the Spanish Academy of Dermatology and Venereology (AEDV) on biologic therapy for psoriasis incorporates information from the most recent publications on this topic.

22 Guideline Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. 2013

Carretero, G / Ribera, M / Belinchón, I / Carrascosa, J M / Puig, Ll / Ferrandiz, C / Dehesa, L / Vidal, D / Peral, F / Jorquera, E / González-Quesada, A / Muñoz, C / Notario, J / Vanaclocha, F / Moreno, J C / Anonymous1280765. ·Grupo de Psoriasis de la Academia Española de Dermatología y Venereología, Spain. gcarrete@aedv.es ·Actas Dermosifiliogr · Pubmed #23891453.

ABSTRACT: Phototherapy, classic systemic treatments (methotrexate, acitretin, and ciclosporin), and biologic agents (etanercept, infliximab, adalimumab, and ustekinumab) constitute a broad therapeutic arsenal that increases the likelihood of achieving control of severe and extensive disease in patients with psoriasis. Acitretin continues to be a very valuable tool in both monotherapy, in which it is combined with other systemic treatments (classic or biologic), and in sequential therapy. Thanks to its lack of a direct immunosuppressive effect and its ability to achieve a long-term response, acitretin has an important role in the treatment of psoriasis, although this has not always been acknowledged in relevant treatment guidelines. We present consensus guidelines for the use of acitretin in psoriasis drawn up by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. These guidelines provide a detailed account of acitretin, including pharmacological properties, indications and contraindications, adverse effects, and factors that should be taken into account to enhance the safe use of this drug. They also propose treatment strategies for use in routine clinical practice. The overall aim of these guidelines is to define the criteria for the use and management of acetretin in psoriasis.

23 Guideline The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. 2013

Coates, Laura C / Tillett, William / Chandler, David / Helliwell, Philip S / Korendowych, Eleanor / Kyle, Stuart / McInnes, Iain B / Oliver, Susan / Ormerod, Anthony / Smith, Catherine / Symmons, Deborah / Waldron, Nicola / McHugh, Neil J / Anonymous440765. ·Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, UK. neil.mchugh@rnhrd.nhs.uk. ·Rheumatology (Oxford) · Pubmed #23887065.

ABSTRACT: -- No abstract --

24 Guideline Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. 2013

Puig, L / Carrascosa, J M / Belinchón, I / Fernández-Redondo, V / Carretero, G / Ruiz-Carrascosa, J C / Careaga, J M / de la Cueva, P / Gárate, M T / Ribera, M / Anonymous5000749 / Anonymous5010749. ·Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. drlpuig@gmail.com ·Actas Dermosifiliogr · Pubmed #23395400.

ABSTRACT: BACKGROUND: Topical therapy is key to the successful management of psoriasis, and patient adherence to treatment contributes to its effectiveness in the long-term. OBJECTIVES: To establish consensus on adherence to topical treatment in psoriasis, draw up recommendations on how adherence could be improved, and evaluate the properties of the main vehicles used. METHOD: We designed a questionnaire on adherence to topical treatments in psoriasis and another on the properties of the main vehicles used; the 2 questionnaires were evaluated using the Delphi method by a panel of experts and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology, respectively. RESULTS: Consensus was reached on the following statements: a) treatment adherence increases the effectiveness of topical treatments in psoriasis; b) to improve adherence, it is necessary to improve communication between patients and health care staff, provide written instructions, and simplify treatment with easy-to-use, pleasant products that are preferably applied only once a day; c) treatment satisfaction increases adherence and tends to improve the health-related quality of life of the patient. Ointment was rated the worst vehicle, while foams and solutions were rated the best. Creams and lipophilic gels were considered to be better than ointment in several respects. CONCLUSION: To improve adherence to topical regimens in psoriasis and the effectiveness of such therapy, we need to give patients more information, simplify treatment regimens, and prescribe easy-to-use products that will ensure satisfaction.

25 Guideline 2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis. 2012

Machado, Pedro / Bogas, Mónica / Ribeiro, Ana / Costa, José / Neto, Adriano / Sepriano, Alexandre / Raposo, Ana / Cravo, Ana Rita / Vilar, António / Furtado, Carolina / Ambrósio, Catarina / Miguel, Cláudia / Vaz, Cláudia / Catita, Cristina / Nour, Dolores / Araújo, Domingos / Vieira-Sousa, Elsa / Teixeira, Filipa / Brandão, Filipe / Canhão, Helena / Cordeiro, Inês / Gonçalves, Inês / Ferreira, Joana / Fonseca, João Eurico / da Silva, José Alberto Pereira / Romeu, José / Ferreira, Júlia / Costa, Lúcia / Maurício, Luís / Cunha-Miranda, Luís / Parente, Manuela / Coutinho, Margarida / Cruz, Margarida / Oliveira, Margarida / Salvador, Maria João / Santos, Maria José / Pinto, Patrícia / Valente, Paula / Abreu, Pedro / Roque, Raquel / Ramiro, Sofia / Capela, Susana / Las, Vera / Barcelos, Anabela / Anonymous1620731. ·Serviço de Reumatologia, Hospitais da Universidade de Coimbra, Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal. pedrommcmachado@gmail.com ·Acta Reumatol Port · Pubmed #22781512.

ABSTRACT: OBJECTIVE: To develop recommendations for the treatment of psoriatic arthritis (PsA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. A draft of the recommendations was first circulated to all Portuguese rheumatologists and their suggestions were incorporated in the draft. At a national meeting the recommendations were discussed and all attending rheumatologists voted on the level of agreement for each recommendation. A second draft was again circulated before publication. RESULTS: A consensus was achieved regarding the initiation, assessment of response and switching biological therapies in patients with PsA. Specific recommendations were developed for several disease domains: peripheral arthritis, axial disease, enthesitis and dactylitis. CONCLUSION: These recommendations may be used for guidance in deciding which patients with PsA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.

Next